Skip to content
To the full analysis

Sanara MedTech stock: Price History and Returns

SMTI
$32.67Closing price of 19 Nov 2026MEQIRI Score 61 out of 100

Sanara MedTech's share price rose by 20.6% a year over the last 10 years, 553.4% in total.

This shows what Sanara MedTech Inc. has returned on the stock market in the past. Past returns say nothing about the future.

Daily figure as of 20 Nov 2026

1 year
+71.4%
since 19 Nov 2025
5 years
+0.8%
a year, +4.3% in total
10 years
+20.6%
a year, +553.4% in total
Since 2007
+9.9%
a year, +553.4% in total

Share Price Since 2007

How Sanara MedTech Has Performed

The stock has not yet recovered its largest drawdown of 99.6% between June 2008 and December 2018 and trades 93.5% below the high today. Since the low in December 2018 the share price has risen more than tenfold. In its best year, 2019, the share price more than doubled at +436.7%, the weakest was 2012 at −90%. 2025 was a weak year at −29.7%, well below the 10-year average of +20.6% a year.

From 2023 to 2025 the stock fell three years in a row. More calendar years ended with a loss than with a gain, 10 of 18 since 2008. Since the start of the year the stock is up 39.9%.

How Sanara MedTech Compares

Over 10 years Sanara MedTech beat the S&P 500: with dividends +20.6% a year against +14.3% for the index, in US dollars. Over one year, Sanara MedTech did better than 95% of the 44 other stocks in the Medical (Instruments & Supplies) industry. Over five years the figure was 71%. The highest share price returns over five years in the Medical (Instruments & Supplies) industry came from Bonesupport Holding, Pulse Biosciences and Asahi Intecc.

PeriodSanara MedTechS&P 500
1 year+71.4%+11%
5 years+0.8%+10.6%
10 years+20.6%+14.3%

Returns of Industry Peers

Among its industry peers, Safilo Group led over one year (+24.9%) and Embecta trailed furthest (−56.2%).

Stock1 year5 years
Safilo Group+24.9%+39.9%
Dynavox Group−14.6%no data
AngioDynamics−9.6%−62.3%
Embecta−56.2%no data
COLTENE Holding+3.6%−54.7%

What Became of $1,000

$1,000 invested in Sanara MedTech 10 years ago is worth $6,534 today.

With dividends means each dividend is reinvested at the closing price on the ex-date, before taxes and costs. The index is represented by an accumulating ETF, dollar amounts at ECB rates. Industry figures are share price returns only, in each exchange's currency, as of 20 Nov 2026.

Returns by Period

PeriodTotalPer year
1 year+71.4%+71.4%
3 years−1.3%−0.4%
5 years+4.3%+0.8%
10 years+553.4%+20.6%
15 years+55.6%+3%
Since 2007+553.4%+9.9%

Returns by Calendar Year

Figures as a table
YearClosing priceReturn
2026 to date$32.67+39.9%
2025$23.35−29.7%
2024$33.20−19.2%
2023$41.10−9.7%
2022$45.50+54%
2021$29.55−40.8%
2020$49.90+209.9%
2019$16.10+436.7%
2018$3.00−50%
2017$6.00+50%
2016$4.00−55.6%
2015$9.00+50%
2014$6.00−45.5%
2013$11.00+175%
2012$4.00−90%
2011$40.000%
2010$40.00−81.8%
2009$220.00−34.3%
2008$335.00+231.7%

Peak Price and Largest Drawdown

High since 2007
$500.00
on 13 Jun 2008, today 93.5% below
Largest drawdown
−99.6%
from the high on 13 Jun 2008 to the low on 10 Dec 2018, the high has not been regained yet

This is the pure share price return in US dollars from closing prices, adjusted for stock splits. Dividends come on top and are not included here.

Work out your own amount and period in the What-if calculator

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Neutral since 7 Nov 2026; valuation signal Fairly valued since 17 Nov 2026
  • Price: closing price of 19 Nov 2026
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.